Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Issue 2 (28th January 2023)

• Record Type: Journal Article
• Authors: Fenlon, Jordan B.; Hutten, Ryan J.; Johnson, Skyler B.; Hu, Boyu; Shah, Harsh; Stephens, Deborah M.; Maity, Amit; Gaffney, David K.; Tao, Randa
• Is Part Of: Leukemia & lymphoma. Volume 64:Issue 2(2023)
• Page Start: 356
• Page End: 363
• Publication Date: 2023-01-28
• Subjects: Radiation -- follicular lymphoma -- low grade -- early stage -- immunotherapy -- rituximab; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2148215
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Radiotherapy (RT) utilization for early-stage, low-grade follicular lymphoma (FL) is low despite treatment guideline recommendations. We compare treatment trends for early-stage FL in the era of involved-site RT and rituximab. We identified 11, 645 patients in the National Cancer Database (NCDB) with stage I–II, grade 1–2 nodal or extranodal FL diagnosed 2011–2017, with median follow-up of 44 months. From 2011 to 2017, RT utilization rates decreased from 33.4% to 22.4%, observation decreased from 65.3% to 49.7%, chemoimmunotherapy increased from 0.5% to 15.0%, immuno-monotherapy increased from 0.6% to 10.2%, and RT + systemic therapy increased from 0.6% to 2.5%. RT utilization remains low in the involved-site RT and rituximab era.